Paediatric Clinical Guidelines is a mobile reference app for NHS clinicians that provides instant access to validated paediatric clinical protocols.
The App DNA
What makes this app unique?
The app removes the version-control friction of traditional print handbooks, ensuring clinicians always access the most current, evidence-based guidance during patient care.
For NHS clinicians, medical trusts, and healthcare professionals requiring mobile access to validated paediatric clinical guidelines.
What does it look like?
Key features
AI-driven search tool that cross-references multiple clinical documents based on user queries.
Cloud-based content management allows immediate distribution of revised clinical guidance to all users.
Dedicated space for clinicians to save and annotate specific guideline sections.
How much does it cost?
The B2B-focused subscription model replaces legacy print-based revenue with recurring digital licensing, ensuring sustainable guideline development.
Velocity
Dormant developmentShow more...
The app has seen no development activity for 204 days, placing it in a zombie state. There have been no feature updates or maintenance patches since the initial release. The lack of any subsequent version history indicates a complete cessation of development momentum.
Who built it?
User Sentiment
What do users think recently?
How are ratings & reviews evolving?
Not enough recent reviews to extract reliable themes yet.
Read the full review analysisCompetition
Competitive landscape for Paediatric Clinical Guidelines
How's the Medical market?
Paediatric Clinical Guidelines serves a specialized B2B medical audience, focusing on the digitization of NHS-validated paediatric protocols. The absence of recent updates since January 2026 suggests a maintenance-mode posture that may limit competitive growth against broader clinical-decision platforms.
Read the market outlookThe rivals identified
Unlock the deeper market read.
Access the full report for freeThe Analyst's Read
Key takeaways for Paediatric Clinical Guidelines
Where is it heading?
The market for clinical reference tools is shifting toward integrated, real-time decision support, placing Paediatric Clinical Guidelines in a position where it must prove its long-term viability through consistent updates. If the current development silence persists, the app risks being replaced by more active, multi-specialty clinical platforms that offer better integration with hospital systems.
- The six-month development gap since the initial release suggests a lack of active maintenance, which undermines the promise of real-time clinical guidance.
- The B2B subscription model provides a stable, non-profit revenue stream that can fund future guideline development if the development cadence resumes.
The SWOT
- Validated clinical content from Partners in Paediatrics (PiP) establishes immediate trust.
- Cloud-based content management ensures all users access the latest evidence-based protocols simultaneously.
- AI-driven search tool reduces the cognitive load of navigating multi-specialty clinical documentation.
- Expansion into additional regional NHS networks could scale the B2B subscription base.
- Integration with Electronic Patient Record (EPR) systems would embed guidelines into clinical workflows.
Next best moves
Resume monthly update cadence because the six-month silence erodes trust in clinical accuracy → improve clinician retention.
The counter-intuitive read
The app's value is not in its AI search…
Read the full takeSince the last report: The platform has pivoted its positioning to emphasize the Partners in Paediatrics (PiP) partnership, while the outlook has declined to mixed due to the ongoing six-month development silence.
Bottom line
Transitioning to a digital-first model provides a foundation for evidence-based care, but the six-month development silence threatens the app's relevance as a primary clinical tool. Resuming a regular update cadence is necessary to maintain trust in the accuracy of the clinical guidance provided.
Unlock 2 critical frictions, 2 market threats and the analyst’s take.
Access the full report for freeSources
- [1] Developer website, source
Report last updated